Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy

Antiviral Therapy

Volumn 14, Issue 5, 2009, Pages 713-722

  Arastéh, Keikawus ^a   Rieger, Armin ^b   Yeni, Patrick ^c   Pozniak, Anton ^d   Boogaerts, Griet ^e   van Heeswijk, Rolf ^e   de Béthune, Marie Pierre ^e   Peeters, Monika ^e   Woodfall, Brian ^e  

^a Vivantes Auguste Viktoria Klinikum   (Germany)

^b Universitatsklinik fur Dermatologie   (Austria)

^c BICHAT HOSPITAL   (France)

^d CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^e TIBOTEC BVBA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; PROTEINASE INHIBITOR; RILPIVIRINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ADULT; ALLERGIC RHINITIS; AMYLASE BLOOD LEVEL; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPEPSIA; ELECTROCARDIOGRAM; FEMALE; FLATULENCE; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERKALEMIA; HYPESTHESIA; IMMUNE RESPONSE; KIDNEY DISEASE; LEUKOCYTE; LYMPHADENOPATHY; LYMPHATIC SYSTEM DISEASE; MALE; MAXIMUM PLASMA CONCENTRATION; MEDIASTINUM DISEASE; MENTAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPHIL; NIGHTMARE; OPEN STUDY; PHASE 2 CLINICAL TRIAL; POLYURIA; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS; SIALOADENITIS; SIDE EFFECT; SLEEP DISORDER; THORAX DISEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY TRACT DISEASE; VERNER MORRISON SYNDROME; VIRUS LOAD;

ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; NITRILES; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 69849087563     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (Updated 3 November 2008. Accessed 7 January 2009.) Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
2. European AIDS Clinical Society. Guidelines for the clinical management and treatment of HIV-infected adults in Europe. (Accessed 3 August 2009.) Available from http://www.europeanaidsclinicalsociety.org/ guidelines.asp
3. Hammer SM, Eron JJ, Jr., Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
4. Richman DD, Morton SC, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004; 18:1393-1401.
5. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment & HIV-1 infection. N Engl J Med 2008; 358:2095-2106.
6. de Béthune M-P, Andries K, Azijn H, et al. TMC278, a new potent NNRTI, with an increased barrier to resistance and good pharmacokinetic profile. 12th Conference on Retroviruses and Opportunistic Infections. 22-25 February 2005, Boston, MA, USA. Abstract and poster 556.
7. Rimsky LT, Azijn H, Tirry I, et al. In vitro resistance profile of TMC278, a next-generation NNRTI: evidence of a higher genetic barrier and a more robust resistance profile than first-generation NNRTIs. XVIII International HIV Drug Resistance Workshop. 9-13 June 2009, Fort Myers, FL, USA. Abstract 120.
8. Janssen PA, Lewi PJ, Arnold E, et al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4- 4-4-[(IE)-2-cyanoethenyl]-2,6-dimethylphenyl] amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J Med Chem 2005; 48:1901-1909.
9. Das K, Bauman JD, Clark AD, Jr., et al. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci U S A 2008; 105:1466-1471.
10. Santoscoy M, Cahn P, Gonzales C, et al. TMC278, an investigational next-generation NNRTI, demonstrates long-term efficacy and tolerability in ARV-naive patients: 96-week results of study C204. XVII International AIDS Conference, 3-8 August 2008, Mexico City, Mexico. Abstract TUAB0103.
11. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med 2004; 12:119-124.
12. Goebel F, Yakovlev A, Pozniak AL, et al. Short-term antiviral activity of TMC278 - a novel NNRTI - in treatment-naive HIV-1-infected subjects. AIDS 2006; 20:1721-1726.